Advertisement

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Opening Session Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Oct
09
Today In Oncology
HER2-Positive Breast Cancer FDA Approves Triplet for Maintenance Therapy
FDA Approves First-Line Pirtobrutinib for CLL-SLL
FDA Approves Lirafugratinib for Previously Treated, Unresectable, Locally Advanced or Metastatic Cholangiocarcinoma
FDA Approves New Labeling of ROS1 Inhibitor for NSCLC
Charles Perou 2026 William L. McGuire Memorial Lecture Award
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo